首页> 外文期刊>Medical dosimetry: official journal of the American Association of Medical Dosimetrists >Field match verification during combination proton, photon, and electron therapy for oligometastatic inflammatory breast cancer
【24h】

Field match verification during combination proton, photon, and electron therapy for oligometastatic inflammatory breast cancer

机译:质子,光子和电子疗法联合治疗寡转移性炎性乳腺癌的现场匹配验证

获取原文
获取原文并翻译 | 示例
       

摘要

Postmastectomy radiation therapy (PMRT) has been shown in randomized trials to improve overall survival for patients with locally advanced breast cancer. The standard PMRT clinical target volume (CTV) encompasses the chest wall and undissected regional lymphatics. Conformal isodose distributions covering the standard CTV with acceptable dose limits to normal tissue can typically be achieved with a combination of photon and electron fields. Field borders are marked on the patient's skin using a light field projection of each beam and are subsequently used to verify daily field matching clinically. Initial imaging of a patient with oligometastatic inflammatory breast cancer demonstrated direct extension of disease from the involved internal mammary lymph node chain into the anterior mediastinum as the only site of metastatic disease. The patient achieved a pathologic complete response to neoadjuvant chemotherapy and underwent mastectomy. The initial sites of gross disease, including the anterior mediastinal node was included in the CTV for PMRT, and treatment planning demonstrated a clear advantage to the inclusion of proton fields in this case. The absence of a light source on the proton delivery system that accurately projects proton field edges onto the patient's skin posed a significant challenge for daily verification of proton-to-photon and -electron field matching. Proton field-specific radiographic imaging devices were designed and used such that proton field edges could be delineated on the patient's skin and used for daily matching with photon and electron fields. Manufacture of the imaging devices was quick and inexpensive. Weekly verification of proton field alignment with the proton field delineation on the skin demonstrated agreement within 3-mm tolerance. The patient remains with no evidence of disease 18 months after completing radiation. Other patients with similar indications may benefit from multimodality radiation therapy.
机译:乳房切除术后放疗(PMRT)已在随机试验中显示,以提高局部晚期乳腺癌患者的总体生存率。标准的PMRT临床目标量(CTV)涵盖了胸壁和未解剖的区域淋巴管。通常可以通过结合光子场和电子场来实现覆盖标准CTV的适形等剂量分布,并且对正常组织的剂量范围是可接受的。使用每个光束的光场投影在患者的皮肤上标记视场边界,然后将其用于临床上验证日常视场匹配。患有低转移性炎性乳腺癌的患者的初步影像显示,疾病从受累的内部乳腺淋巴结链直接延伸到前纵隔,成为转移性疾病的唯一部位。该患者对新辅助化疗取得了病理完全缓解,并接受了乳房切除术。包括前纵隔淋巴结在内的大部疾病的初始部位已包括在PMRT的CTV中,并且治疗计划在这种情况下显示出明显的优势。质子传递系统上缺少光源,无法将质子场边缘准确投射到患者的皮肤上,这对日常验证质子到光子和电子场的匹配提出了重大挑战。设计和使用质子场专用放射线成像设备,以便可以在患者的皮肤上描绘质子场边缘,并用于与光子场和电子场的日常匹配。成像装置的制造是快速且廉价的。每周验证质子场与皮肤上的质子场划界一致,证明在3毫米的公差范围内一致。放疗18个月后,患者仍无疾病迹象。其他适应症相似的患者可能会受益于多模式放射治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号